MEDCL.PA · MedinCell S.A

-

Please sign in to comment on MEDCL.PA

1 Comment

Admin

4 years, 1 month ago

MedinCell S.A is currently in a long term downtrend where the price is trading 18.1% below its 200 day moving average.

From a valuation standpoint, the stock is 58.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 112.3.

MedinCell S.A's total revenue sank by 0.0% to $2M since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-4M since the same quarter in the previous year.

Finally, its free cash flow grew by 26.3% to $-3M since the same quarter in the previous year.

Based on the above factors, MedinCell S.A gets an overall score of 2/5.

ISIN	FR0004065605
Sector	Healthcare
Industry	Biotechnology
Exchange	PA
CurrencyCode	EUR

Market Cap	517M
PE Ratio	None
Target Price	22.4
Beta	0.98
Dividend Yield	None

ABOUT

MedinCell S.A

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.

MEDCL.PA · MedinCell S.A

-

MedinCell S.A

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest MedinCell S.A using a moving average strategy